TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06417567

Intervention type: DRUG
Intervention: NEPA
Description: NEPA in Preventing Postoperative Nausea and Vomiting after General Anesthesia Gastrointestinal Cancer Surgery
Study: NCT04584775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)
Description: Acupuncture is a physical treatment modality that uses thin needles to stimulate specific points on the body in order to manipulate neurologic mechanisms to control specific symptoms and/or physiologic processes.~Chinese herbal medicine is a phytotherapeutic treatment modality that uses herbs, minerals and rarely animal products which are orally administered.~Tuina is a form of massage and physical therapy. Chinese dietetics is a nutritional therapy according to the theoretical principle of traditional Chinese medicine.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
Study: NCT05970679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Atorvastatin 10/5 mg
Description: DW1125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5mg
Description: DW1125A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe 10mg
Description: DW1125E

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 10mg
Description: DW1125A-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1125 placebo
Description: Ezetimibe/Atorvastatin 10/5 mg placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DW1125 placebo
Description: Ezetimibe/Atorvastatin 10/5 mg placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DW1125 placebo
Description: Ezetimibe/Atorvastatin 10/5 mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1125A placebo
Description: Atorvastatin 5mg placebo
Study: NCT05217615

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
Study: NCT05656534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). Suvorexant (SUV) will be placed in opaque capsules with dextrose filler. After the pre-treatment visits participants will take one pill of SUV at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete an EMG. Laboratory assessments will occur during peak concentration, 2 hours post-ingestion. At the end of the visit, participants will be given a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side effects and potential drug-drug interactions. At the end of the 28 days, participants will complete post-treatment lab visits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). The placebo pill will be identical in appearance to suvorexant but will contain only dextrose. Following the pre-treatment visits, participants will take one pill at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete the EMG paradigm. At the end of the visit participants will be provided a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side. At the end of the 28 days, participants will complete post-treatment lab visits.
Study: NCT06117306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4 Methylenedioxymethamphetamine
Description: 1 MDMA session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4 Methylenedioxymethamphetamine
Description: 1 MDMA session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: 12 90-minute PE sessions; initial two sessions both occurring during the first treatment visit, third and fourth sessions occurring during the MDMA session, and the remaining sessions occurring daily or every other day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: 12 90-minute PE sessions; initial two sessions both occurring during the first treatment visit, third and fourth sessions occurring during the MDMA session, and the remaining sessions occurring daily or every other day
Study: NCT05157386

Intervention type: OTHER
Intervention: Braining
Description: Core components of Braining: Personnel-led training sessions, motivating contact with psychiatric staff, measurement and evaluation before and after the training period; usually 12 weeks. PE is added on to treatment as usual (TAU). The training sessions are moderate to intense aerobic group training, 30-45 minutes. Each training session is preceded by a short (5-10 minutes) individual meeting with staff including assessment of daily form, motivational work, and the opportunity to ask questions. The target frequency for participation is preferably at least three training sessions/week during a 12 week period. The training period for each patient begins with an informative and motivating group or individual lecture or and an individual introductory meeting with staff including psychiatric and somatic examination, self-assessment scales for symptoms and quality of life, and blood samples. The training period ends with a meeting with staff with follow-up on the parameters.
Study: NCT04921436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery
Description: prophylactic use of antibiotic-inhibitors
Study: NCT05532189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with BTB autograft with internal brace augmentation (suture tape)
Description: The ACL will be reconstructed using a participant's own patella tendon (BTB autograft), and the graft will be fortified by suture tape during the surgery in order to strengthen it.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction with BTB autograft without internal brace augmentation (suture tape)
Description: The ACL will be reconstructed using a participant's own patella tendon (BTB autograft). The graft will not be fortified by suture tape in this group. It will be used as is without any modification.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Rehabilitation Protocol
Description: Participants will undergo a standardized rehabilitation protocol with twice weekly physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Rehabilitation Protocol
Description: Participants will undergo a standardized rehabilitation protocol with twice weekly physical therapy
Study: NCT05090696

Intervention type: DEVICE
Intervention: Mechanical In-Exsufflator (MI-E)
Description: The feasibility will be estimated by quantifying relief and discomfort of four MI-E sessions (2 days x 2 sessions = 4 sessions). Vital signs will be also noted before and after such MI-E session.
Study: NCT06268704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: This is a non-particulate steroid commonly used to treat SI joint pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: This is a particulate steroid commonly used to treat SI joint pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine HCl Injection
Description: Lidocaine is a local anesthetic used in SI joint injection procedures to numb the procedure site and helps to confirm SI joint dysfunction when injected with the steroid medication into the SI joint.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine HCl Injection
Description: Lidocaine is a local anesthetic used in SI joint injection procedures to numb the procedure site and helps to confirm SI joint dysfunction when injected with the steroid medication into the SI joint.
Study: NCT04676529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5505
Description: PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5505
Description: PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5505
Description: PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5505
Description: PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5505
Description: PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
Study: NCT05642728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management follow-up program
Description: The case manager will monitor asthma control (asthma control test, ACT) and adherence to treatment with questionnaires (inhaler adherence test, TAI) and electronic prescription withdrawal (e-prescription). The case manager will make decisions based on these results and according to pre-designed medical instructions. In addition, the patient will be able to contact the case manager for advice during periods of worsening symptoms. The patient will contact the case manager via a mobile app with messaging and video call option, as well as a contact phone number and email for consultations.
Study: NCT06313736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Brings Change Project (15-minute adult version)
Description: The ABC Project is a self-guided online single-session intervention based on principles of behavioral activation. In a slightly different form intended for adolescents, it has demonstrated efficacy in several studies. Its adult version has also shown some efficacy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Brings Change Project (10-minute adult version)
Description: This is a 10-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Brings Change Project (6-minute adult version)
Description: This is a 6-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Brings Change Project (2-minute adult version)
Description: This is a 2-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
Study: NCT05322954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25mg orally followed by 25 mg or 50 mg orally
Study: NCT06172959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal Intonation Therapy (VIT)
Description: Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Vocal Intonation Therapy is a music therapy technique consisting of breathing and vocal exercises to target respiratory function and vocal quality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Singing (TS)
Description: Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Therapeutic Singing is a music therapy technique used to work on the rehabilitation of vocal and respiratory function.
Study: NCT05970679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DW1125A placebo
Description: Atorvastatin 5mg placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DW1125A placebo
Description: Atorvastatin 5mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1125E placebo
Description: Ezetimibe 10mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1125E placebo
Description: Ezetimibe 10mg placebo
Study: NCT06281730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz New Generation Fetoscope - curved 11508AAK
Description: 11508AAK Miniature straight forward telescope 0-degree set, curved, diameter 3.3 millimeter, length 30 centimeter, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 French., remote eyepiece, fiber optic light transmission incorporated.
Study: NCT05970679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DW1125E placebo
Description: Ezetimibe 10mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1125A-1 placebo
Description: Atorvastatin 10mg placebo
Study: NCT06281730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz New Generation Fetoscope - straight 11506AAK
Description: 11506AAK Miniature straight forward telescope 0-degree, straight, diameter 3.3 millimeter, length 30 cm, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 french, remote eyepiece, fiber optic light transmission incorporated.
Study: NCT05970679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1125A-1 placebo
Description: Atorvastatin 10mg placebo
Study: NCT05177965

Intervention type: OTHER
Intervention: Exposure to shift work
Description: Detailed questionnaire adapted from the Standard Shiftwork Index, measured at inclusion
Study: NCT06647238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Intervention in lipid therapy
Description: Pharmacist intervention may include but is not limited to prescribing (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc.), patient education, and medication access.
Study: NCT05609565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
Description: spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
Study: NCT05970679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DW1125A-1 placebo
Description: Atorvastatin 10mg placebo
Study: NCT05609565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia with bupivacaine
Description: spinal anesthesia with bupivacaine
Study: NCT05907785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The intervention will consist of recommendations to improve physical activity (PA) and dietary habits. It is based on the PAIDO Programme (www.programapaido.es), an outpatient family-based multidisciplinary programme that combines PA, education on nutrition, and behavioural therapy. It will last 6 months and improvement of metabolic health and body weight loss is expected, particularly in the groups with overweight and obesity. The dietary intervention will be focused on the promotion of the Mediterranean diet, with follow-up and advice from a dietitian-nutritionist. Participants will be encouraged in reducing sedentary behaviour (watching television, playing computer games, playing board games). Performance of aerobic and strength physical exercises will be scheduled, progressively increasing the intensity. Volunteers and their parents will participate in monthly sessions to follow-up on adherence to the PA and dietary recommendations and give personalized advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The intervention will consist of recommendations to improve physical activity (PA) and dietary habits. It is based on the PAIDO Programme (www.programapaido.es), an outpatient family-based multidisciplinary programme that combines PA, education on nutrition, and behavioural therapy. It will last 6 months and improvement of metabolic health and body weight loss is expected, particularly in the groups with overweight and obesity. The dietary intervention will be focused on the promotion of the Mediterranean diet, with follow-up and advice from a dietitian-nutritionist. Participants will be encouraged in reducing sedentary behaviour (watching television, playing computer games, playing board games). Performance of aerobic and strength physical exercises will be scheduled, progressively increasing the intensity. Volunteers and their parents will participate in monthly sessions to follow-up on adherence to the PA and dietary recommendations and give personalized advice.
Study: NCT06208098

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Salivary cortisol dosage
Description: saliva sample at 8 - 9h \& at T30
Study: NCT05278962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2i
Description: empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No SGLT2i
Description: No SGLT2i
Study: NCT05280496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is used to lower blood sugar in patients with high blood sugar (diabetes).
Study: NCT05880199

Intervention type: DEVICE
Intervention: Body surface gastric mapping device
Description: A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.

Intervention type: DEVICE
Intervention: Body surface gastric mapping device
Description: A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.
Study: NCT05138653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to CVL-354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Capsule
Study: NCT05737485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCT1100
Description: RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
Study: NCT04607005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will continue to receive Standard of care as they are used to before entry in the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Participants will continue to receive Standard of care as they are used to before entry in the study.